As Byetta Lawsuits Move Forward, Bernstein Liebhard LLP Notes New FDA Review of Additional Incretin
The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic medications used to treat Type 2 diabetes. New York, New York (PRWEB) February 13, 2014 As Byetta lawsuits (http://www.byettalawsuit.com) and other legal claims involving incretin mimetic drugs continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that U.S. health regulators have launched a safety review of two other medications in that class due to concerns over a possible assoc
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 313
- Bankruptcy 44
- Business 134
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 609
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4